Vipoglanstat clinical trials
Also written GS-248.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses vipoglanstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Gesynta Pharma AB (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test vipoglanstat.
- Jun 2027A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With EndometriosisPhase 2 · Gesynta Pharma AB
Studies
Open first, then newest update. How each study uses vipoglanstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With EndometriosisActive, not recruitingPhase 2Gesynta Pharma ABNCT07260669Written as Vipoglanstat
- A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic SclerosisCompletedPhase 2Gesynta Pharma ABNCT04744207Written as GS-248
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248CompletedPhase 1Gesynta Pharma ABNCT04036227Written as GS-248
Codes
What other systems call vipoglanstat · ClinicalTrials.gg INT016577
- UNII (FDA) FN57BDR4DAVIPOGLANSTATOne source FDA
- NCI Thesaurus C190446VipoglanstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FN57BDR4DA | VIPOGLANSTAT | One source FDA |
| NCI Thesaurus | C190446 | Vipoglanstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.